Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

Molecular neurobiology 20120801

Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.

The International journal of neuroscience 20120701

Drugs for treating Parkinson disease.

Nursing 20120701

Development of Parkinson's disease in patients with Narcolepsy.

Journal of neural transmission (Vienna, Austria : 1996) 20120601

Hyposmia in Parkinson's disease.

Psychiatry and clinical neurosciences 20120601

Livedo reticularis associated with rasagiline (azilect).

Journal of drugs in dermatology : JDD 20120601

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

Journal of clinical pharmacology 20120501

Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.

Mechanisms of ageing and development 20120501

Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).

Bioorganic & medicinal chemistry 20120501

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

Journal of neural transmission (Vienna, Austria : 1996) 20120401

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Drugs 20120326

Modeling mitochondrial dysfunctions in the brain: from mice to men.

Journal of inherited metabolic disease 20120301

Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.

Retina (Philadelphia, Pa.) 20120301

Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

European journal of neurology 20120201

Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.

The International journal of neuroscience 20120101

A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

PloS one 20120101

Tinnitus: network pathophysiology-network pharmacology.

Frontiers in systems neuroscience 20120101

Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients.

Parkinson's disease 20120101

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.

Neuropsychiatric disease and treatment 20120101

From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

Journal of Alzheimer's disease : JAD 20120101

Restless legs syndrome responsive to rasagiline treatment: a case report.

Clinical neuropharmacology 20120101

Combined beneficial effect of rasagiline on motor function and depression in de novo PD.

Clinical neuropharmacology 20120101

α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease.

PloS one 20120101

Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases.

Oxidative medicine and cellular longevity 20120101

Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Neuropsychiatric disease and treatment 20120101

Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.

Bioorganic & medicinal chemistry 20111215

Drugs in traffic: the road to approval.

Nature medicine 20111206

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

European journal of neurology 20111201

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

CNS drugs 20111201

Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.

Movement disorders : official journal of the Movement Disorder Society 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.

European journal of pharmacology 20111130

In the news: Doubt over Azilect® relabeling.

Nature reviews. Neurology 20111115

Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

Movement disorders : official journal of the Movement Disorder Society 20111101

Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.

Current topics in medicinal chemistry 20111101

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

The neurologist 20111101

An effective novel delivery strategy of rasagiline for Parkinson's disease.

International journal of pharmaceutics 20111031

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20111001

Advanced strategies for treatment of Parkinson's disease: the role of early treatment.

The American journal of managed care 20111001

Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

The International journal of neuroscience 20110901

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

Movement disorders : official journal of the Movement Disorder Society 20110815

Disease modification in Parkinson's disease.

Drugs & aging 20110801

Safety of rasagiline for the treatment of Parkinson's disease.

Expert opinion on drug safety 20110701

TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.

Circulation. Heart failure 20110701

Treatment in late Parkinson's disease.

Annals of Indian Academy of Neurology 20110701

Motor fluctuations and dyskinesias (diagnosis and management).

Annals of Indian Academy of Neurology 20110701

Initiation of treatment in early PD (evidences based).

Annals of Indian Academy of Neurology 20110701

The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.

British journal of pharmacology 20110601

Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.

Expert opinion on pharmacotherapy 20110601

Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.

Current genomics 20110601

Medical management of Parkinson's disease: focus on neuroprotection.

Current neuropharmacology 20110601

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

The Lancet. Neurology 20110501

Milestones in Parkinson's disease therapeutics.

Movement disorders : official journal of the Movement Disorder Society 20110501

MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.

Journal of proteome research 20110401

Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica.

European journal of medicinal chemistry 20110401

Determination of minimal clinically important change in early and advanced Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20110401

Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

Antioxidants & redox signaling 20110301

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Journal of neural transmission (Vienna, Austria : 1996) 20110301

Hemiparkinsonism-hemiatrophy syndrome.

Archives of Iranian medicine 20110301

Rasagiline-induced serotonin syndrome.

Movement disorders : official journal of the Movement Disorder Society 20110301

MAO-inhibitors in Parkinson's Disease.

Experimental neurobiology 20110301

Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.

Drugs & aging 20110201

MAO inhibitors.

Cleveland Clinic journal of medicine 20110201

Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.

Journal of glaucoma 20110101

Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.

Neurochemistry international 20110101

Selegiline and rasagiline: twins or distant cousins?

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101

Iron and mechanisms of neurotoxicity.

International journal of Alzheimer's disease 20110101

From L-dopa to dihydroxyphenylacetaldehyde: a toxic biochemical pathway plays a vital physiological function in insects.

PloS one 20110101

Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.

BMC pharmacology 20110101

The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

International journal of molecular sciences 20110101

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Patient preference and adherence 20110101

Available and emerging treatments for Parkinson's disease: a review.

Drug design, development and therapy 20110101

Placebo - More hatred than love.

Journal of neurosciences in rural practice 20110101

Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.

PloS one 20110101

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

Journal of neuroinflammation 20110101

Influence of stochastic gene expression on the cell survival rheostat after traumatic brain injury.

PloS one 20110101

Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

Current medicinal chemistry 20110101

Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

BMC neurology 20110101

[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

The pharmacology of selegiline.

International review of neurobiology 20110101

Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

International review of neurobiology 20110101

Rasagiline in Parkinson's disease.

International review of neurobiology 20110101

Selective inhibitors of monoamine oxidase type B and the 'cheese effect'.

International review of neurobiology 20110101

Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Advances in pharmacological sciences 20110101

The evidence for disease modification in Parkinson's disease.

The International journal of neuroscience 20110101

The promise of neuroprotective agents in Parkinson's disease.

Frontiers in neurology 20110101

Strategies for reducing or preventing the generation of oxidative stress.

Oxidative medicine and cellular longevity 20110101

Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives.

Oxidative medicine and cellular longevity 20110101

Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Journal of drug delivery 20110101

Variable initial swing side and prolonged double limb support represent abnormalities of the first three steps of gait initiation in patients with Parkinson's disease with freezing of gait.

Frontiers in neurology 20110101

Lack of information and access to advanced treatment for Parkinson's disease patients.

Journal of multidisciplinary healthcare 20110101

Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

ISRN neurology 20110101

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.

Journal of clinical pharmacology 20101201

Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Neurochemical research 20101201

Seniors with Parkinson's disease: initial medical treatment.

Journal of clinical neurology (Seoul, Korea) 20101201

The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Neurology 20101123

The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Neurology 20101123

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

Progress in neurobiology 20101101

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.

Neurochemistry international 20101101

Does rasagiline have a disease-modifying effect on Parkinson's disease?

Current neurology and neuroscience reports 20101101

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Archives of toxicology 20101101

[Rasagiline: effectiveness and protection in Parkinson's disease].

Revista de neurologia 20101101

[Disease-modifying therapies in PD].

Rinsho shinkeigaku = Clinical neurology 20101101

Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.

European journal of neurology 20100901

Isolated delusional syndrome in Parkinson's Disease.

Parkinsonism & related disorders 20100901

Slowing the decline.

Nature 20100826

Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.

The American journal of geriatric pharmacotherapy 20100801

Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.

Parkinsonism & related disorders 20100701

Rasagiline improves learning and memory in young healthy rats.

Behavioural pharmacology 20100701

Transdermal rotigotine for the perioperative management of Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20100701

Discordant effects of rasagiline doses in Parkinson disease.

Nature reviews. Neurology 20100701

Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.

Current Alzheimer research 20100601

The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.

The Journal of pharmacology and experimental therapeutics 20100601

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

The Lancet. Neurology 20100601

Long-term efficacy of rasagiline in early Parkinson's disease.

The International journal of neuroscience 20100601

Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.

Experimental neurobiology 20100601

A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.

Biological psychiatry 20100501

Parkinson's disease and motor fluctuations.

Current treatment options in neurology 20100501

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Neurology 20100406

The delayed-start study in Parkinson disease: can't satisfy everyone.

Neurology 20100406

Reply to Drs. Olanow and Rascol.

Neurology 20100406

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.

Journal of neurochemistry 20100301

[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

Fortschritte der Neurologie-Psychiatrie 20100301

Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.

Nature reviews. Neurology 20100301

Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.

The American journal of managed care 20100301

Rasagiline in Parkinson's disease.

The New England journal of medicine 20100218

Rasagiline in Parkinson's disease.

The New England journal of medicine 20100218

TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.

The Journal of pharmacology and experimental therapeutics 20100201

Levodopa delivery systems: advancements in delivery of the gold standard.

Expert opinion on drug delivery 20100201

Skin cancer and Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20100130

Selective MAO-B inhibitors have low potential for the tyramine effect.

Movement disorders : official journal of the Movement Disorder Society 20100115

The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices.

Neuropharmacology 20100101

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

BMC neuroscience 20100101

Anticipatory modulation of digit placement for grasp control is affected by Parkinson's disease.

PloS one 20100101

Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.

Neuro-degenerative diseases 20100101

The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.

Neuro-degenerative diseases 20100101

The role of rasagiline in the treatment of Parkinson's disease.

Clinical interventions in aging 20100101

GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons.

BMC neuroscience 20100101

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.

Journal of Alzheimer's disease : JAD 20100101

Methods for studying redox cycling of thioredoxin in mediating preconditioning-induced survival genes and proteins.

Methods in enzymology 20100101

What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?

Neuroepidemiology 20100101

Delayed start, rapid solution?

Neuroepidemiology 20100101

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Core evidence 20100101

Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

Current pharmaceutical design 20100101

Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.

Neuropsychobiology 20100101

Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Clinical drug investigation 20100101

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Neuropsychiatric disease and treatment 20100101

Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease.

BMC neurology 20100101

[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].

Nederlands tijdschrift voor geneeskunde 20100101

The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

Frontiers in neuroscience 20100101

[Statistical significance or clinical relevance?].

Nederlands tijdschrift voor geneeskunde 20100101

Treatment of advanced Parkinson's disease.

Parkinson's disease 20100101

[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

Biopsable neural tissues: toward new biomarkers for Parkinson's disease?

Frontiers in psychiatry 20100101

Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.

ClinicoEconomics and outcomes research : CEOR 20100101

Mao-B inhibitor know-how: back to the pharm.

Neurology 20091208

Parkinson's disease I: glucocerebrosidase mutations, family history of melanoma and questionable effects of rasagiline.

Journal of neurology 20091201

New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy.

Parkinsonism & related disorders 20091201

Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.

Progress in neuro-psychopharmacology & biological psychiatry 20091113

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Journal of neural transmission (Vienna, Austria : 1996) 20091101

Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20091101

Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.

Journal of neural transmission (Vienna, Austria : 1996) 20091101

Rasagiline-induced spontaneous ejaculation.

Movement disorders : official journal of the Movement Disorder Society 20091030

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

The New England journal of medicine 20090924

Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.

Neurotoxicity research 20090801

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

Expert review of neurotherapeutics 20090801

Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres.

Journal of pharmaceutical and biomedical analysis 20090712

Alzheimer's disease: new approaches to drug discovery.

Current opinion in chemical biology 20090601

Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

International journal of molecular sciences 20090601

Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20090415

MAO-B inhibitor know-how: back to the pharm.

Neurology 20090414

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

Neurotoxicity research 20090401

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20090315

Involvement of the subthalamic nucleus in engagement with behaviourally relevant stimuli.

The European journal of neuroscience 20090301

'Bad guys' among the antiparkinsonian drugs.

Psychiatria Danubina 20090301

Targeting the progression of Parkinson's disease.

Current neuropharmacology 20090301

Neuroprotection by rasagiline in thiamine deficient rats.

Brain research 20090223

Mechanisms compensating for dopamine loss in early Parkinson disease.

Neurology 20090217

[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

Ideggyogyaszati szemle 20090130

Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

BMC medical genomics 20090101

Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

The open neurology journal 20090101

Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.

European review for medical and pharmacological sciences 20090101

A review of ropinirole prolonged release in Parkinson's disease.

Clinical interventions in aging 20090101

Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture.

PloS one 20090101

Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.

PloS one 20090101

[Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.

Drugs & aging 20090101

Role of rasagiline in treating Parkinson's disease: Effect on disease progression.

Therapeutics and clinical risk management 20090101

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Cases journal 20090101

Sleep attack associated to rotigotine.

Clinical neuropharmacology 20090101

An unusual case of spontaneous multi vessel coronary artery dissection in an elderly patient: a case report.

Cases journal 20090101

Screening the methanol extracts of some Iranian plants for acetylcholinesterase inhibitory activity.

Research in pharmaceutical sciences 20090101

Drug selection and timing of initiation of treatment in early Parkinson's disease.

Annals of neurology 20081201

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Movement disorders : official journal of the Movement Disorder Society 20081115

Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Expert opinion on pharmacotherapy 20081101

Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).

Acta crystallographica. Section C, Crystal structure communications 20081101

Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081001

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Fortschritte der Neurologie-Psychiatrie 20081001

Neuropharmacology.

Indian journal of pharmacology 20081001

The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.

Chemico-biological interactions 20080925

Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.

Hypertension (Dallas, Tex. : 1979) 20080901

TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.

Journal of cardiovascular pharmacology 20080901

Rasagiline in neurodegeneration.

Experimental neurology 20080801

Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H(2)O(2) release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria.

Journal of bioenergetics and biomembranes 20080801

The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.

Neuropsychiatric disease and treatment 20080801

Current approaches to the treatment of Parkinson's disease.

Neuropsychiatric disease and treatment 20080801

New frontiers in the pharmacological management of Parkinson's disease.

Drugs of today (Barcelona, Spain : 1998) 20080701

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.

Journal of neurochemistry 20080601

[Rasagiline in Parkinson's disease].

Neurologia (Barcelona, Spain) 20080501

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.

Experimental neurology 20080401

Progress in neuroprotection in Parkinson's disease.

European journal of neurology 20080401

Protection against Parkinson's disease progression: clinical experience.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20080401

Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

Genes, brain, and behavior 20080301

Discovery and characterization of a putrescine oxidase from Rhodococcus erythropolis NCIMB 11540.

Applied microbiology and biotechnology 20080301

[A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301

New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.

Bioorganic & medicinal chemistry 20080215

Rasagiline improves freezing in a patient with primary progressive freezing gait.

Movement disorders : official journal of the Movement Disorder Society 20080215

Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.

Journal of biomolecular structure & dynamics 20080201

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Neuropsychiatric disease and treatment 20080201

Drugs for Parkinson’s disease: levodopa is still the gold standard.

Neuropsychiatric disease and treatment 20080201

Rasagiline in treatment of Parkinson's disease.

Neuropsychiatric disease and treatment 20080201

Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Journal of neural transmission (Vienna, Austria : 1996) 20080101

Spotlight on rasagiline in Parkinson's disease.

CNS drugs 20080101

Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

CNS drugs 20080101

The clinical pharmacology of intranasal l-methamphetamine.

BMC clinical pharmacology 20080101

Medical treatment of freezing of gait.

Movement disorders : official journal of the Movement Disorder Society 20080101

Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.

BMC neuroscience 20080101

[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20071201

Pharmacotherapy for Parkinson's disease.

Pharmacotherapy 20071201

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Pharmacotherapy 20071201

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.

Annals of the New York Academy of Sciences 20071201

Parkinson disease: an incremental challenge.

South Dakota medicine : the journal of the South Dakota State Medical Association 20071201

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.

Journal of neurochemistry 20071001

Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.

Neurochemical research 20071001

Transdermal selegiline for the treatment of major depressive disorder.

Neuropsychiatric disease and treatment 20071001

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Clinical therapeutics 20070901

Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Journal of neural transmission (Vienna, Austria : 1996) 20070801

Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

Current opinion in neurology 20070801

The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

Molecular pharmacology 20070601

Rasagiline as a therapy for Parkinson's disease (PD).

The American journal of geriatric pharmacotherapy 20070601

Editorial.

Therapeutics and clinical risk management 20070601

Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

Therapeutics and clinical risk management 20070601

Biological targets for isatin and its analogues: Implications for therapy.

Biologics : targets & therapy 20070601

Advances in the pharmacologic management of early Parkinson disease.

The neurologist 20070501

Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20070430

The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection.

Antioxidants & redox signaling 20070201

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

Neurobiology of disease 20070101

Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

Journal of neural transmission (Vienna, Austria : 1996) 20070101

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Clinical neuropharmacology 20070101

From a Parkinson's disease expert: Rasagiline and the future of therapy.

Molecular neurodegeneration 20070101

Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

CNS drugs 20070101

Rasagiline: a review of its use in the management of Parkinson's disease.

Drugs 20070101

Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Drugs & aging 20070101

Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.

BMC neuroscience 20070101

Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.

Journal of neural transmission. Supplementum 20070101

New strategies in motor parkinsonism.

Parkinsonism & related disorders 20070101

Rasagiline (Azilect) for Parkinson's disease.

The Medical letter on drugs and therapeutics 20061204

L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.

Pharmacology, biochemistry, and behavior 20061201

Rasagiline. Parkinson's disease: a simple me-too.

Prescrire international 20061201

The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

Current Alzheimer research 20061201

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Neurotoxicity research 20061201

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

The American journal of geriatric pharmacotherapy 20061201

Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

British journal of pharmacology 20061101

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

Journal of the neurological sciences 20061025

New pharmacologic horizons in the treatment of Parkinson disease.

Neurology 20061010

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

Movement disorders : official journal of the Movement Disorder Society 20061001

A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061001

Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.

Neurology 20060523

Clinical trials with rasagiline: evidence for short-term and long-term effects.

Neurology 20060523

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515

[Diagnosis and therapy of idiopathic Parkinson's disease].

MMW Fortschritte der Medizin 20060515

Safety of rasagiline in elderly patients with Parkinson disease.

Neurology 20060509

Rasagiline improves quality of life in patients with early Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20060501

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Neurology 20060411

Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

The Annals of pharmacotherapy 20060401

Rasagiline -- is there a place for this drug in managing Parkinson's disease?

International journal of clinical practice 20060201

Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.

International journal of clinical practice 20060201

N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

Journal of neural transmission (Vienna, Austria : 1996) 20060101

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

British journal of pharmacology 20060101

Drugs in development for Parkinson's disease: an update.

Current opinion in investigational drugs (London, England : 2000) 20060101

CROPPER: a metagene creator resource for cross-platform and cross-species compendium studies.

BMC bioinformatics 20060101

Concerning neuroprotective therapy for Parkinson's disease.